Quantbot Technologies LP grew its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 236.6% during ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the upcoming ...

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a buy rating in a report ...

Burning Rock Biotech Limited’s BNR share price has dipped by 12.36%, which has investors questioning if this is right time to ...

VAEs also introduce mathematical constraints that accommodate computational models called large neural networks. To continue with the example of large language models, these neural networks can be ...

The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

ADHD likely has a genetic component. If a biological parent or sibling has ADHD, you’re more likely to have it, too, but this doesn’t mean you will. Your environment can be influential as well.

Analyst Price Forecast Suggests 84.10% Upside As of March 4, 2025, the average one-year price target for Myriad Genetics is $18.87/share. The forecasts range from a low of $8.08 to a high of $30.45.